If you or someone you know feels dramatically worse in cold weather—crushing fatigue, fingers turning blue, dark urine—the culprit might be cold agglutinin disease (CAD), commonly called “anemia cold.” This is a rare form of autoimmune hemolytic anemia where your immune system produces antibodies that attack and destroy your own red blood cells when your body temperature drops. It affects roughly 16 per million people, with a median age of onset around 65 years old.
What makes CAD uniquely frustrating is that something as simple as stepping outside in winter or reaching into the freezer can trigger a hemolytic episode. The good news: once properly diagnosed, most patients can be managed effectively with a combination of cold avoidance, targeted therapies, and in some cases, newer complement-inhibiting drugs that have changed the treatment landscape since 2022.
What Exactly Happens in Cold Agglutinin Disease?
Your immune system produces IgM antibodies (called cold agglutinins) that bind to red blood cells at temperatures below core body temperature—typically between 3°C and 37°C. When these antibodies latch on, they activate the complement cascade, a chain reaction in your immune system that essentially punches holes in your red blood cells or tags them for destruction in the liver.
The result is extravascular hemolysis—your liver and spleen chew through red blood cells faster than your bone marrow can replace them. Hemoglobin drops. Bilirubin rises. You feel terrible.
A critical concept here is thermal amplitude—the highest temperature at which the cold agglutinins remain active. Patients whose antibodies agglutinate red cells at or near 37°C (body temperature) tend to have far more severe disease than those whose antibodies only activate at 4°C. Thermal amplitude matters more than antibody titer for predicting clinical severity.
Causes and Risk Factors
CAD falls into two categories:
Primary (Idiopathic) CAD
This accounts for the majority of cases and is now recognized as a clonal lymphoproliferative disorder of the bone marrow. A small population of B-cells produces the pathogenic IgM. It’s not a full-blown lymphoma, but it sits on that spectrum. Most patients are over 60.
Secondary Cold Agglutinin Syndrome (CAS)
This form is triggered by an identifiable underlying condition:
- Infections: Mycoplasma pneumoniae (classically in younger adults) and Epstein-Barr virus are the most common triggers. These cases are usually self-limiting.
- Lymphoproliferative disorders: Non-Hodgkin lymphoma, Waldenström’s macroglobulinemia, and chronic lymphocytic leukemia.
- Autoimmune diseases: Systemic lupus erythematosus and other connective tissue disorders.
Symptoms: What CAD Actually Feels Like
Symptoms range from mild inconvenience to life-threatening anemia. Most patients experience a chronic baseline anemia punctuated by acute exacerbations in cold weather.
| Symptom | Cause | How Common |
|---|---|---|
| Chronic fatigue and weakness | Low hemoglobin from ongoing hemolysis | Nearly universal |
| Acrocyanosis (blue fingers, toes, ears, nose) | Red cell agglutination in peripheral capillaries | ~90% of patients |
| Raynaud’s-like phenomena | Cold-triggered vascular changes | Common |
| Jaundice (yellow skin/eyes) | Elevated bilirubin from red cell breakdown | Moderate to severe cases |
| Dark or cola-colored urine | Hemoglobinuria from intravascular hemolysis | During acute episodes |
| Livedo reticularis | Agglutination in skin vasculature | Less common |
Hemoglobin levels in CAD patients typically hover between 8–10 g/dL at baseline but can plummet to 5–6 g/dL during acute crises. Many patients also develop mild to moderate splenomegaly and show elevated reticulocyte counts (the bone marrow’s attempt to compensate).
Diagnosis: The Tests You Need
Getting the right diagnosis often takes time—CAD is rare enough that many clinicians don’t think of it first. Here’s what a proper workup looks like:
- Direct antiglobulin test (DAT/Coombs test): Positive for complement C3d but negative for IgG. This pattern is the hallmark of CAD and distinguishes it from warm autoimmune hemolytic anemia.
- Cold agglutinin titer: Typically ≥64 at 4°C. Titers in primary CAD often exceed 1:1,000 and can reach 1:512,000.
- Thermal amplitude testing: Determines the highest temperature at which agglutination occurs. High thermal amplitude (≥30°C) correlates with more severe disease.
- Hemolysis markers: Elevated LDH, elevated indirect bilirubin, low haptoglobin, reticulocytosis.
- Bone marrow biopsy: Recommended to rule out underlying lymphoproliferative disease. In primary CAD, you’ll often see a clonal B-cell population.
- CT imaging: To evaluate for lymphadenopathy or organomegaly suggesting secondary causes.
Pro tip for labs: Blood samples must be kept at 37°C from draw to processing. If the sample cools, red cells agglutinate in the tube and results—especially CBC and blood typing—become unreliable. Tell your lab in advance.
Treatment Strategies for Cold Agglutinin Disease
1. Cold Avoidance (First-Line for Everyone)
This isn’t just “wear a coat.” Patients need to protect extremities aggressively, warm IV fluids before infusion, avoid cold beverages in severe cases, and consider relocating to warmer climates if feasible. For patients with mild disease and low thermal amplitude, cold avoidance alone may be sufficient.
2. Rituximab-Based Therapy
Rituximab (anti-CD20 monoclonal antibody) is the standard first-line drug therapy when treatment is needed. It targets the clonal B-cells producing the pathogenic IgM. Response rates with rituximab monotherapy are around 50%, with median response duration of about 1 year. Combining rituximab with bendamustine pushes response rates to approximately 70–80% with longer-lasting remissions—but carries more toxicity.
3. Complement Inhibitors (Game-Changer)
Sutimlimab (Enjaymo) was FDA-approved in February 2022 specifically for CAD—the first targeted therapy for this disease. It blocks C1s, the first step in the classical complement pathway, halting hemolysis without immunosuppression. In the CARDINAL trial, 54% of patients achieved the composite endpoint of hemoglobin increase ≥2 g/dL without transfusion. Responses can be seen within one week.
4. Transfusion Support
Transfusions are used for symptomatic severe anemia (hemoglobin <7 g/dL or cardiovascular instability). Blood must be warmed through an in-line warmer to prevent transfused cells from being immediately destroyed. Crossmatching can be challenging—notify the blood bank early.
What Doesn’t Work
Steroids and splenectomy—the mainstays of warm autoimmune hemolytic anemia—are largely ineffective in CAD. Hemolysis in CAD is primarily complement-mediated and hepatic (not splenic), so removing the spleen doesn’t help. Steroids show response rates under 15%. Don’t waste time on them.
When to See a Doctor
Seek medical evaluation promptly if you experience:
- Persistent fatigue that doesn’t improve with rest, especially if worse in cold weather
- Bluish discoloration of fingers, toes, or ears when exposed to cold
- Dark or tea-colored urine, especially after cold exposure
- Yellowing of skin or eyes (jaundice)
- Known CAD with hemoglobin dropping below 8 g/dL or new cardiovascular symptoms (chest pain, shortness of breath at rest, dizziness)
If you’ve been diagnosed with CAD, request a referral to a hematologist experienced with complement-mediated anemias. This is not a condition most primary care physicians manage regularly.
Frequently Asked Questions
Is cold agglutinin disease the same as cold sensitivity or Raynaud’s?
No. While CAD can cause Raynaud’s-like symptoms (blue, painful fingers in the cold), the underlying mechanism is completely different. Raynaud’s is a vasospastic disorder. CAD involves antibody-mediated destruction of red blood cells. The acrocyanosis in CAD comes from red cells clumping in small blood vessels, not from vessel spasm. The two can coexist, but CAD requires specific blood tests to diagnose.
Can cold agglutinin disease go away on its own?
Secondary CAS caused by infections like Mycoplasma pneumoniae or EBV typically resolves within weeks to months as the infection clears. Primary CAD, however, is a chronic condition. It may wax and wane with seasons, but it doesn’t spontaneously remit. Most patients need long-term management.
How dangerous is CAD? Can it be fatal?
Primary CAD is a serious but generally manageable condition. Median survival is comparable to age-matched populations when appropriately treated. However, severe acute hemolytic crises can be life-threatening, and chronic anemia increases cardiovascular risk. Thromboembolic events are also more common in CAD patients—one study found a venous thromboembolism rate roughly 3 times higher than the general population.
What hemoglobin level is typical in CAD patients?
Most patients with primary CAD have a baseline hemoglobin between 8–10 g/dL. During acute exacerbations (cold exposure, illness), it can drop to 5–6 g/dL or lower. About 40% of CAD patients require at least one blood transfusion. After starting sutimlimab, many patients see their hemoglobin rise to near-normal levels (≥12 g/dL).
Should I move to a warmer climate if I have CAD?
It depends on disease severity and thermal amplitude. Patients with low thermal amplitude who only agglutinate at very cold temperatures may do fine with simple precautions. Those with high thermal amplitude (agglutination near body temperature) will have symptoms regardless of climate and need pharmacologic therapy. That said, many patients do report meaningful symptom improvement after relocating to warmer areas—it’s a reasonable consideration if your disease is temperature-dependent and lifestyle permits.
